Indian Clinical Trials Sector Slowing Down
The Indian clinical trials sector is likely entering a period of slowdown as a result of a "vague regulatory structure" and the failure of the Indian government to appreciate or understand the sector, reports BioSpectrum Asia.
Contract research organization (CRO) sector representatives at the Clinical Trials Asian Summit 2012 expressed concern about the slowdown in approved clinical trials in India, which fell from 855 in 2010 to just 791 in 2011-a 7.5% decrease.
Experts interviewed at the conference cited delays in clinical trial approval, inadequately trained review staff and a disinterested government as being the cause of the slowdown.
As a result of the regulatory structure, companies are increasingly looking to Eastern Europe and South East Asia, said one expert to BioSpectrum.
Read More: BioSpectrum Asia - Indian clinical trial industry losing momentum, warn industry captains